SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00299949

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Use of Whole Blood and Cell-rich Coagulation Assays for the Detection of Non-Overt DIC in Sepsis

Sepsis is the 13th most common cause of death in the United States, causing approximately 210,000 deaths per year. Once DIC has developed, irreversible organ injury has already occurred and the mortality rate is 70%. Inhibition of systemic coagulation with activated protein C concentrate has been the only therapy for sepsis introduced in the past several decades which has improved outcomes. Elucidation of the coagulopathic mechanisms early in the development of DIC may give rise to targeted therapies and strategies for early intervention. We hypothesize that an increase in endogenous thrombin potential precedes the development of overt DIC by a clinically significant time period. Our primary objective is to determine if endogenous thrombin potential (ETP) measured at first diagnosis of sepsis prior to the onset of DIC and organ failure is predictive of overt DIC and/or poor outcome. We will compare ETP to standard coagulation assays and the clinical assessment of DIC using the ISTH criteria for overt DIC. A secondary objective of this study is to determine if host coagulation variables predispose to the development of DIC and poor clinical outcome during sepsis.

NCT00299949 Sepsis Disseminated Intravascular Coagulation
MeSH: Sepsis Disseminated Intravascular Coagulation
HPO: Disseminated intravascular coagulation Sepsis


Primary Outcomes

Description: ETP will be used to predict 28 day mortality

Measure: Mortality

Time: 28 days

Time Perspective: Prospective

Case-Only


There is one SNP

SNPs


1 G20210A

Cbc, PT/PTT, Fibrinogen, d-dimer, Protein C activity, Protein S activity, ATIII activity, Factor V Leiden mutation, Prothrombin G20210A mutation analysis will be performed in Memorial Herman Hospital clinical laboratories. --- G20210A ---

The secondary objective will be to compare host coagulation variables, including ETP, roTEG, Pro C, Pro S, ATIII, FVL, and prothrombin G20210A mutation at presentation, with the secondary outcome measures of 28-day mortality and organ dysfunction. --- G20210A ---



HPO Nodes


HPO:
Disseminated intravascular coagulation
Genes 20
RARA HELLPAR IRF2BP2 SERPIND1 ZBTB16 NLRC4 NPM1 CFI NABP1 PML CFH BCOR PRKAR1A TBL1XR1 CD46 STAT3 STAT5B PROS1 FIP1L1 NUMA1
Sepsis
Genes 74
ECE1 TGM1 NRTN BLNK CYBB ATP7A IKZF1 AK2 ALOXE3 CYBA FERMT3 RAG1 NCF1 LIG4 EDN3 CXCR4 PGM3 CD79B COG4 PIK3R1 CHD7 SEMA3C SERAC1 TFRC CYP4F22 SAMD9 FOXP3 WIPF1 MNX1 RET HYOU1 HLA-B MYLK BTK IGHM PLEC DCLRE1C LRRC8A RAG1 RAG2 IL7R ABCA12 CTNNB1 EDNRB IL2RG IL2RG NIPAL4 NCF4 IGLL1 LIPN MYH11 AK2 ITGB4 ADA LMOD1 ELANE SULT2B1 TCF3 CD79A IL7R ALOX12B SEMA3D GALT APC GDNF MMUT SDR9C7 NCF2 RMRP WAS ACTG2 CYBC1 NFKB2 G6PC3